Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4704826 | 1.00 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL4702927 | 0.85 | MAPT (0.50) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL1881149 | 0.85 | MAPT (0.50) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL1878678 | 0.85 | MAPT (0.58) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL1878680 | 0.85 | MAPT (0.58) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL4704058 | 0.83 | MAPT (0.48) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL1883139 | 0.83 | MAPT (0.48) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL4702681 | 0.83 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL5529874 | 0.83 | MAPT (0.56) | MAPTALDH1A1HTTGAAHPGD | |
| SCHEMBL1871869 | 0.82 | MAPT (0.55) | MAPTALDH1A1HTTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648896-B1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INT (ES) | 2008-02-13 | — | — | EP | disclosed |
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | FERRER INTERNACIONAL S.A. (ES) | 2007-02-22 | — | — | US | disclosed |
| EP-1648896-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO [1,5-A] PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014596-A1 | 7-SUBSTITUTED 3-NITRO-PYRAZOLO `1,5-A! PYRIMIDINES | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043064-A1 | 7-Substituted 3-nitro-pyrazo[1,5-a] pyrimidines | GABRB1, GABRA1, GABRB2 | MAPT 2772/4885ALDH1A1 113/4885HTT 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.